528 related articles for article (PubMed ID: 3401800)
21. [3H]Spiperone labels non-cyclase-linked dopamine receptors in the ventral tegmental area of rat brain.
Gundlach AL; McDonald D; Beart PM
J Neurochem; 1982 Sep; 39(3):890-4. PubMed ID: 7097294
[TBL] [Abstract][Full Text] [Related]
22. Ontogeny of dopamine D1 receptors in rat striatum.
Zeng WY; Hyttel J; Murrin LC
J Neurochem; 1988 Mar; 50(3):862-7. PubMed ID: 2963092
[TBL] [Abstract][Full Text] [Related]
23. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
24. Dietary lithium during development: changes in amino acid levels, ionic content, and [3H]spiperone binding in the brain of rats.
Wajda IJ; Banay-Schwartz M; De Guzman T; Manigault I
Neurochem Res; 1983 May; 8(5):637-48. PubMed ID: 6412150
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the binding of [3H]spiperone and [3H]domperidone in homogenates of mammalian retina and caudate nucleus.
Watling KJ; Iversen LL
J Neurochem; 1981 Nov; 37(5):1130-43. PubMed ID: 7299392
[TBL] [Abstract][Full Text] [Related]
26. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
Wilmot CA; Szczepanik AM
Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.
Neve KA; Altar CA; Wong CA; Marshall JF
Brain Res; 1984 Jun; 302(1):9-18. PubMed ID: 6428705
[TBL] [Abstract][Full Text] [Related]
28. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum.
Fuxe K; Meller E; Goldstein M; Benfenati F; Agnati LF
Neurosci Lett; 1986 Feb; 64(2):163-8. PubMed ID: 3960398
[TBL] [Abstract][Full Text] [Related]
29. Binding of 3H-spiperone and 3H-(-)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands.
Urwyler S; Coward D
Naunyn Schmiedebergs Arch Pharmacol; 1987 Feb; 335(2):115-22. PubMed ID: 2951601
[TBL] [Abstract][Full Text] [Related]
30. Lasting changes in high affinity 3H-spiperone binding to the rat striatum and mesolimbic area after chronic methamphetamine administration: evaluation of dopaminergic and serotonergic receptor components.
Akiyama K; Sato M; Kashihara K; Otsuki S
Biol Psychiatry; 1982 Dec; 17(12):1389-402. PubMed ID: 7159638
[TBL] [Abstract][Full Text] [Related]
31. 3- and 4-O-sulfoconjugated and methylated dopamine: highly reduced binding affinity to dopamine D2 receptors in rat striatal membranes.
Werle E; Lenz T; Strobel G; Weicker H
Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):28-34. PubMed ID: 2853303
[TBL] [Abstract][Full Text] [Related]
32. [3H]Spiperone binding sites in brain: autoradiographic localization of multiple receptors.
Palacios JM; Niehoff DL; Kuhar MJ
Brain Res; 1981 Jun; 213(2):277-89. PubMed ID: 7248759
[TBL] [Abstract][Full Text] [Related]
33. Dopamine receptor binding in inbred mice: strain differences in mesolimbic and nigrostriatal dopamine binding sites.
Boehme RE; Ciaranello RD
Proc Natl Acad Sci U S A; 1981 May; 78(5):3255-9. PubMed ID: 6166945
[TBL] [Abstract][Full Text] [Related]
34. Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity.
Dewar KM; Montreuil B; Grondin L; Reader TA
J Pharmacol Exp Ther; 1989 Aug; 250(2):696-706. PubMed ID: 2527300
[TBL] [Abstract][Full Text] [Related]
35. Prolonged inhibition of striatal dopamine receptor sites by isofloxythepin.
Lau YS; Runice C
Eur J Pharmacol; 1985 Oct; 116(1-2):25-31. PubMed ID: 2865162
[TBL] [Abstract][Full Text] [Related]
36. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
37. Pre- and postnatal ontogeny and characterization of dopaminergic D2, serotonergic S2, and spirodecanone binding sites in rat forebrain.
Bruinink A; Lichtensteiger W; Schlumpf M
J Neurochem; 1983 May; 40(5):1227-36. PubMed ID: 6834058
[TBL] [Abstract][Full Text] [Related]
38. 3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans.
Barrio JR; Satyamurthy N; Huang SC; Keen RE; Nissenson CH; Hoffman JM; Ackermann RF; Bahn MM; Mazziotta JC; Phelps ME
J Cereb Blood Flow Metab; 1989 Dec; 9(6):830-9. PubMed ID: 2531146
[TBL] [Abstract][Full Text] [Related]
39. Muscarine-binding sites localized to cortical dopamine terminals.
Liskowsky DR; Potter LT
Neurosci Lett; 1985 Jul; 58(2):229-33. PubMed ID: 2931625
[TBL] [Abstract][Full Text] [Related]
40. Striatal D1- and D2-dopamine receptor sites are separately detectable in vivo.
Leslie CA; Bennett JP
Brain Res; 1987 Jul; 415(1):90-7. PubMed ID: 2957025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
